Reliq Health: Technology Solutions to Revolutionize Healthcare

February 2, 2021

A cloud-based, in-home or in-facility, patient monitoring technology that is changing healthcare

Reliq Health Technologies is a rapidly growing technology company focused on developing innovative remote patient monitoring, care collaboration and telemedicine solutions for community-based healthcare.

According to CEO, Dr. Lisa Crossley, 20 percent of all the population have chronic diseases. Further, that 20 percent accounts for roughly 80 percent of health care spending. She also believes the reason for that is that on a day-to-day basis, these patients are responsible for their own care management in the home, and that tends not to be very effective.

Reliq's virtual care platform uses a high tech, low touch approach to provide high-quality healthcare in the community setting while reducing the cost of care delivery.

"We've generated a lot of clinical data that demonstrate the efficacy of our platform and that patients genuinely do have better health outcomes, reduced hospital admissions, E.R. visits, etc.", says Crossley.

iUGO Care

iUGO CARE is a wholly-owned subsidiary of Reliq Health Technologies. Moreover, it's a powerful platform for care coordination and home healthcare. It integrates wearables, sensors, voice technology with intuitive mobile apps and desktop software for patients, families, clinicians, and healthcare administrators.

The platform provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

"This will be a real breakout year for Reliq. We expect to achieve cash flow positive this quarter, so by the end of March 2021 and profitability, the following quarter," says Crossley.

For more information on Reliq Health Technologies Inc. (TSX.V: RHT, OTCQB: RQHTF) please fill out the form below.

You might also like

Healthcare
Lexaria Bioscience: Transforming GLP-1 Drug Delivery for a Growing Market

Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Healthcare
Sernova: Advancing the Future of Diabetes Treatment

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!